CD276 and breast carcinoma: Zirconium-89 (89Zr)-labeled anti-B7-H3 monoclonal antibody DS-5573a is another validated B7-H3 targeting imaging approach, where PET/MRI evaluation demonstrated promising in vivo biodistribution and stability of 89Zr-DS-5573a and revealed specific and prolonged targeting of B7-H3-positive tumors [217], further demonstrating the potential of B7-H3 in either target imaging or target immunotherapy, although mainly in the field of breast cancer, B7-H3 has shown its potential in tumor imaging.